• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Canadian Journal of Emergency Medicine >Tamsulosin for treatment of unilateral distal ureterolithiasis: a systematic review and metaanalysis
【24h】

Tamsulosin for treatment of unilateral distal ureterolithiasis: a systematic review and metaanalysis

机译：坦洛新治疗单侧远端输尿管结石症：系统评价和荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives:The lifetime prevalence of ureterolithiasis is approximately 13% for men and 7% for women in the United States. Tamsulosin, an α-antagonist, has been used as therapy to facilitate the expulsion of lithiasis. Whether it is a good treatment for distal lithiasis remains controversial. We conducted a systematic review and meta-analysis to evaluate the effect of tamsulosin on the passage of distal ureterolithiasis.Methods:A systematic search was conducted using MEDLINE, EMBASE, and Cochrane Central. Trial eligibility was evaluated by two investigators. All randomized controlled trials (RCTs) comparing tamsulosin to standard therapy or placebo for the treatment of a single distal ureterolithiasis ≤ 10 mm in adult patients with renal colic confirmed by radiographic imaging were included. Data extraction was conducted in duplicate. Primary outcome was the expulsion rate, and secondary outcomes were the mean time for ureterolithiasis expulsion, analgesic requirements, and side effects. Mantel-Haenszel random effect models were used, and heterogeneity was assessed using I2 statistics. Data were presented with relative risks (RRs).Results:The search strategy identified 685 articles, of which 22 studies were included. Combined results suggested a benefit for the expulsion of ureterolithiasis (≥ 10 mm) when tamsulosin was used compared to a standard treatment (RR 1.50 [95% CI 1.31–1.71], I2 = 70%). A decrease in the average time of expulsion of the ureterolithiasis of 3.33 days in favour of tamsulosin was observed (95% CI ?4.23, ?2.44], I2 = 67%).Conclusion:Tamsulosin increases the rate of spontaneous passage of distal ureterolithiasis (≤ 10 mm).
机译：目的：在美国，输尿管结石的终生患病率男性约为13％，女性约为7％。坦索罗辛是一种α拮抗剂，已被用作促进结石排出的疗法。对于远端结石的治疗是否有效仍存在争议。我们进行了系统的综述和荟萃分析，以评估坦洛新对远端输尿管结石症的影响。方法：使用MEDLINE，EMBASE和Cochrane Central进行系统搜索。两名研究者对试验资格进行了评估。所有通过放射线照相成像证实的成年肾绞痛患者中，将坦索罗辛与标准疗法或安慰剂用于治疗≤10 mm的单个远端输尿管结石的随机对照试验（RCT）均包括在内。一式两份进行数据提取。主要结局是驱逐率，次要结局是输尿管结石的平均时间，镇痛要求和副作用。使用了Mantel-Haenszel随机效应模型，并使用I2统计量评估了异质性。结果：检索策略共鉴定出685篇文章，其中包括22项研究。综合结果表明，与标准治疗相比，使用坦索罗辛治疗可改善输尿管结石症（≥10 mm）（RR 1.50 [95％CI 1.31-1.71]，I2 = 70％）。观察到输尿管结石的平均时间减少了3.33天，有利于坦索罗辛（95％CI≤4.23，≤2.44，I2 = 67％）。结论：坦索罗辛增加了远端输尿管结石的自发通过率（ ≤10毫米）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号